Can thymosin alpha 1 cause cancer?

This site's thymosin alpha-1 citations do not measure cancer incidence as an outcome. They report a 98-person hepatitis B trial (complete virological response at 18 months in 40.6% after a 26-week course versus 9.4% of untreated controls) and the TESTS sepsis trial (1,106 adults; 28-day mortality 23.4% versus 24.1% on placebo). Cancer supportive care is listed as a research area, which is not a counted cancer-cause finding. This FAQ does not invent a cancer rate from silence.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of further names and published absences. Leftover harvested questions after the first two absence sets: more brand versus molecule names, side effects the citations did not count, compounding formulas this catalogue does not hold, national FDA and Australia fields, trial windows rather than an onset clock, named combinations with no interaction table, and oral routes that have not been studied.